Exploring the Epidemiology of Cancer after Solid Organ Transplantation (EpCOT): an observational cohort study
暂无分享,去创建一个
[1] L. Magder,et al. Cancer‐attributable mortality among solid organ transplant recipients in the United States: 1987 through 2014 , 2019, Cancer.
[2] Katherine E Henson,et al. Data Resource Profile: National Cancer Registration Dataset in England , 2019, International journal of epidemiology.
[3] A. Teixeira-Pinto,et al. Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant. , 2019, Journal of the American Society of Nephrology : JASN.
[4] R. Steenkamp,et al. Chapter 5 Survival and Cause of Death in UK Adult Patients on Renal Replacement Therapy in 2016: National and Centre-specific Analyses , 2018, Nephron.
[5] B. Kasiske,et al. Clinical and Economic Consequences of Early Cancer After Kidney Transplantation in Contemporary Practice , 2017, Transplantation.
[6] S. Kim,et al. Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[7] A. Green,et al. Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta‐Analysis , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[8] A. Keogh,et al. Iatrogenic immunosuppression and risk of non‐Hodgkin lymphoma in solid organ transplantation: A population‐based cohort study in Australia , 2016, British journal of haematology.
[9] Albert Lee. ‘Bolam’ to ‘Montgomery’ is result of evolutionary change of medical practice towards ‘patient-centred care’ , 2016, Postgraduate Medical Journal.
[10] A. Keogh,et al. High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: A population-based cohort study. , 2016, Journal of the American Academy of Dermatology.
[11] A. Sharif,et al. Cancer‐related outcomes in kidney allograft recipients in England versus New York State: a comparative population‐cohort analysis between 2003 and 2013 , 2016, Cancer medicine.
[12] S. Kim,et al. Cancer Mortality Among Recipients of Solid-Organ Transplantation in Ontario, Canada. , 2016, JAMA oncology.
[13] Anirudh Rao,et al. UK Renal Registry 18th Annual Report (December 2015) Chapter 5: Survival and Causes of Death in UK Adult Patients on Renal Replacement Therapy in 2014: National and Centre-specific Analyses , 2016, Nephron.
[14] E. Geissler. Post-transplantation malignancies: here today, gone tomorrow? , 2015, Nature Reviews Clinical Oncology.
[15] E. Engels,et al. Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis , 2015, Cancer medicine.
[16] A. Wiseman. Induction Therapy in Renal Transplantation: Why? What Agent? What Dose? We May Never Know. , 2015, Clinical journal of the American Society of Nephrology : CJASN.
[17] R. Pfeiffer,et al. Association of Antibody Induction Immunosuppression With Cancer After Kidney Transplantation , 2015, Transplantation.
[18] G. Danan,et al. Tacrolimus and the Risk of Solid Cancers After Liver Transplant: A Dose Effect Relationship , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[19] A. Courtney,et al. The Clinical Course of Kidney Transplant Recipients After 20 Years of Graft Function , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[20] A. Sharif. Sirolimus after kidney transplantation , 2014, BMJ : British Medical Journal.
[21] A. Sharif,et al. Malignancy-related mortality following kidney transplantation is common. , 2014, Kidney international.
[22] M. Guba,et al. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients , 2013, Transplant international : official journal of the European Society for Organ Transplantation.
[23] D. Brennan,et al. Selection of induction therapy in kidney transplantation , 2013, Transplant international : official journal of the European Society for Organ Transplantation.
[24] A. Keogh,et al. De novo Cancer‐Related Death in Australian Liver and Cardiothoracic Transplant Recipients , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[25] Hermann Brenner,et al. Kidney Graft Survival in Europe and the United States: Strikingly Different Long-Term Outcomes , 2013, Transplantation.
[26] J. Craig,et al. Important outcomes for kidney transplant recipients: a nominal group and qualitative study. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[27] M. Tonelli,et al. Penny wise, pound foolish? Coverage limits on immunosuppression after kidney transplantation. , 2012, The New England journal of medicine.
[28] A. Israni,et al. Spectrum of cancer risk among US solid organ transplant recipients. , 2011, JAMA.
[29] J. Neuberger,et al. Comparison of the Incidence of Malignancy in Recipients of Different Types of Organ: A UK Registry Audit , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[30] A. Webster,et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. , 2010, Journal of the American Society of Nephrology : JASN.
[31] SUPPORTING TABLES,et al. KDIGO clinical practice guideline for the care of kidney transplant recipients. , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[32] C. Vajdic,et al. Cancer incidence and risk factors after solid organ transplantation , 2009, International journal of cancer.
[33] B. Kiberd,et al. Cancer Mortality in Kidney Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[34] P. Halloran,et al. Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.
[35] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[36] C. Parkinson,et al. Management of solid tumours in organ-transplant recipients. , 2007, The Lancet. Oncology.
[37] M. Falster,et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.
[38] H. Goldschmidt,et al. Malignancy in renal transplantation. , 2004, Journal of the American Society of Nephrology : JASN.
[39] B. Kasiske,et al. Cancer after Kidney Transplantation in the United States , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[40] J. Fox,et al. Contemporary Practice , 1996 .
[41] F. Luan,et al. Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[42] Á. Gutiérrez-Dalmau,et al. Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients , 2012, Drugs.